Value of 18FDG PET for prediction of therapeutic response in HER2+ breast cancer: Interim analysis

M. Chanchou; M.-A. Mouret-Reynier; A. Cougoul; E. Deshayes; V. D’Hondt; K. Bourahla; T. Petit; S. Bardet; C. Levy; O. Morel; P. Augereau; C. Rousseau; M. Campone; J. Monteil; L. Venat-Bouvet; V. Benavent; F. Cachin

doi:10.1016/j.mednuc.2020.02.003

Value of 18FDG PET for prediction of therapeutic response in HER2+ breast cancer: Interim analysis

Médecine Nucléaire ◽

10.1016/j.mednuc.2020.02.003 ◽

2020 ◽

Vol 44 (3) ◽

pp. 181-188

Author(s):

M. Chanchou ◽

M.-A. Mouret-Reynier ◽

A. Cougoul ◽

E. Deshayes ◽

V. D’Hondt ◽

...

Keyword(s):

Breast Cancer ◽

Interim Analysis ◽

Therapeutic Response ◽

Her2 Breast Cancer ◽

18Fdg Pet

Download Full-text

Anti-cancer resource use in the initial management of advanced HER2+ breast cancer: An interim analysis of the UK ESTHER study

European Journal of Cancer ◽

10.1016/s0959-8049(18)30572-0 ◽

2018 ◽

Vol 92 ◽

pp. S116

Author(s):

A. Wardley ◽

J. Fredriksson ◽

I. Leslie ◽

T. Batten ◽

A. Ring

Keyword(s):

Breast Cancer ◽

Resource Use ◽

Interim Analysis ◽

Initial Management ◽

Her2 Breast Cancer ◽

Anti Cancer ◽

The Uk

Download Full-text

Abstract PS10-50: Patterns of use of a trastuzumab biosimilar (ABP 980) in patients with HER2+ breast cancer treated in clinical practice in Europe: An interim analysis from an observational chart review study (GARDENIA)

10.1158/1538-7445.sabcs20-ps10-50 ◽

2021 ◽

Author(s):

Joanna Kufel-Grabowska ◽

Tevy San ◽

Antonio Bernardo ◽

Luigi Cavanna ◽

Isaura Fernandez Perez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Interim Analysis ◽

Chart Review ◽

Her2 Breast Cancer ◽

Patterns Of Use ◽

Review Study

Download Full-text

Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

10.1158/1538-7445.am2017-ct162 ◽

2017 ◽

Author(s):

Kaitlin M. Peace ◽

Jennifer K. Litton ◽

Rashmi Murthy ◽

Timothy J. Vreeland ◽

Diane F. Hale ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Breast Cancer Patients ◽

Her2 Breast Cancer ◽

Randomized Phase Ii

Download Full-text

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response

BMC Cancer ◽

10.1186/s12885-016-2377-z ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 14

Author(s):

Sharath Gangadhara ◽

Chris Smith ◽

Peter Barrett-Lee ◽

Stephen Hiscox

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Therapeutic Response ◽

3D Culture ◽

Her2 Breast Cancer

Download Full-text

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

Breast Cancer Research ◽

10.1186/s13058-016-0793-2 ◽

2017 ◽

Vol 19 (1) ◽

Cited By ~ 24

Author(s):

David Groheux ◽

Antoine Martineau ◽

Luis Teixeira ◽

Marc Espié ◽

Patricia de Cremoux ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Texture Analysis ◽

Clinicopathological Parameters ◽

Breast Cancer Patients ◽

Her2 Breast Cancer ◽

18Fdg Pet ◽

Pet Ct

Download Full-text

ALTTO trial seeks to define best therapy for HER2 breast cancer

PsycEXTRA Dataset ◽

10.1037/e459002008-001 ◽

2008 ◽

Author(s):

Daryl McGrath

Keyword(s):

Breast Cancer ◽

Her2 Breast Cancer

Download Full-text

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

The Lancet ◽

10.1016/s0140-6736(98)05071-5 ◽

1998 ◽

Vol 352 (9145) ◽

pp. 98-101 ◽

Cited By ~ 222

Author(s):

T Powles

Keyword(s):

Breast Cancer ◽

Interim Analysis ◽

Royal Marsden Hospital ◽

Chemoprevention Trial

Download Full-text

Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated or Homologous Recombination Deficient (HRD) Advanced Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct03931551 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Homologous Recombination ◽

Advanced Breast Cancer ◽

Cancer Susceptibility ◽

Susceptibility Gene ◽

Breast Cancer Susceptibility ◽

Advanced Breast ◽

Breast Cancer Susceptibility Gene ◽

Her2 Breast Cancer ◽

Cancer Susceptibility Gene

Download Full-text

Faculty Opinions recommendation of ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737201214.793572775 ◽

2020 ◽

Author(s):

Vijay Tiwari ◽

Deborah Lavin

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Therapeutic Response ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8707964.9224064 ◽

2011 ◽

Author(s):

Simon Cook ◽

Pam Lochhead

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Cyclin E ◽

Breast Cancer Patients ◽

Trastuzumab Resistance ◽

Her2 Breast Cancer

Download Full-text